SK288052B6 - Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it - Google Patents
Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it Download PDFInfo
- Publication number
- SK288052B6 SK288052B6 SK5020-2004A SK50202004A SK288052B6 SK 288052 B6 SK288052 B6 SK 288052B6 SK 50202004 A SK50202004 A SK 50202004A SK 288052 B6 SK288052 B6 SK 288052B6
- Authority
- SK
- Slovakia
- Prior art keywords
- bilastine
- polymorph
- antihistaminic
- preparing
- pharmaceutical preparation
- Prior art date
Links
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960004314 bilastine Drugs 0.000 title claims abstract description 49
- 230000001387 anti-histamine Effects 0.000 title abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 6
- 230000003266 anti-allergic effect Effects 0.000 title abstract description 5
- 239000000739 antihistaminic agent Substances 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000013078 crystal Substances 0.000 claims abstract description 6
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 28
- 238000002329 infrared spectrum Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 150000001298 alcohols Chemical class 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000000862 absorption spectrum Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- -1 2-ethoxyethyl Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2002/000194 WO2003089425A1 (es) | 2002-04-19 | 2002-04-19 | POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK50202004A3 SK50202004A3 (sk) | 2005-05-05 |
| SK288052B6 true SK288052B6 (sk) | 2013-03-01 |
Family
ID=29225789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK5020-2004A SK288052B6 (sk) | 2002-04-19 | 2002-04-19 | Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7612095B2 (cs) |
| EP (1) | EP1505066B1 (cs) |
| JP (1) | JP5142448B2 (cs) |
| KR (1) | KR100673140B1 (cs) |
| CN (1) | CN1290843C (cs) |
| AR (1) | AR039423A1 (cs) |
| AT (1) | ATE347550T1 (cs) |
| AU (1) | AU2002255017B2 (cs) |
| BG (1) | BG66302B1 (cs) |
| BR (1) | BRPI0215703B8 (cs) |
| CA (1) | CA2484460C (cs) |
| CY (2) | CY1107564T1 (cs) |
| CZ (1) | CZ305162B6 (cs) |
| DE (1) | DE60216641T2 (cs) |
| DK (1) | DK1505066T3 (cs) |
| ES (1) | ES2278018T3 (cs) |
| HR (1) | HRP20041048B1 (cs) |
| HU (1) | HU230032B1 (cs) |
| IL (1) | IL164645A (cs) |
| MX (1) | MXPA04010313A (cs) |
| NO (1) | NO329327B1 (cs) |
| NZ (1) | NZ536551A (cs) |
| PA (1) | PA8571201A1 (cs) |
| PE (1) | PE20040086A1 (cs) |
| PT (1) | PT1505066E (cs) |
| SI (1) | SI1505066T1 (cs) |
| SK (1) | SK288052B6 (cs) |
| UA (1) | UA76866C2 (cs) |
| UY (1) | UY27762A1 (cs) |
| WO (1) | WO2003089425A1 (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体 |
| US20140194111A1 (en) * | 2011-06-30 | 2014-07-10 | Panasonic Corporation | Communication system, user terminal, and communication device |
| CN102675101B (zh) * | 2012-05-16 | 2014-01-29 | 王蕾 | 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法 |
| CZ307500B6 (cs) | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
| CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
| WO2014188453A2 (en) * | 2013-05-24 | 2014-11-27 | Msn Laboratories Private Limited | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid |
| CN103356616A (zh) * | 2013-06-29 | 2013-10-23 | 北京万全德众医药生物技术有限公司 | 一种含有比拉斯汀的药物组合物及其制备方法 |
| CN104447682A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 比拉斯汀化合物 |
| CN104398481A (zh) * | 2014-10-29 | 2015-03-11 | 万全万特制药江苏有限公司 | 比拉斯汀口崩片及其制备方法 |
| WO2017017301A1 (es) * | 2015-07-24 | 2017-02-02 | Urquima, S.A | Formas cristalinas de bilastina y procedimientos para su preparación |
| EP3170816A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
| EP3170817A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
| WO2017167949A1 (en) | 2016-04-01 | 2017-10-05 | Krka, D.D., Novo Mesto | Crystalline forms of bilastine |
| EP3452462A4 (en) * | 2016-05-05 | 2019-10-23 | MSN Laboratories Private Limited, R&D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
| ES2813561T3 (es) | 2017-09-07 | 2021-03-24 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende bilastina |
| EP3470062B1 (en) | 2017-12-18 | 2020-10-28 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate |
| ES2864176T3 (es) | 2017-12-18 | 2021-10-13 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua |
| MA51612B1 (fr) | 2018-01-18 | 2021-06-30 | Faes Farma Sa | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant |
| EP4267109A1 (en) | 2020-12-23 | 2023-11-01 | Noucor Health S.A. | A non-micronized bilastine composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
| ES2124167B1 (es) * | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| EE200100529A (et) * | 1999-04-16 | 2002-12-16 | Dr. Reddy's Research Foundation | Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid |
| PL351684A1 (en) * | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
-
2002
- 2002-04-19 HU HU0500241A patent/HU230032B1/hu unknown
- 2002-04-19 DE DE60216641T patent/DE60216641T2/de not_active Expired - Lifetime
- 2002-04-19 AU AU2002255017A patent/AU2002255017B2/en not_active Expired
- 2002-04-19 BR BRPI0215703A patent/BRPI0215703B8/pt active IP Right Grant
- 2002-04-19 UA UA20041109444A patent/UA76866C2/uk unknown
- 2002-04-19 DK DK02724323T patent/DK1505066T3/da active
- 2002-04-19 CA CA002484460A patent/CA2484460C/en not_active Expired - Fee Related
- 2002-04-19 EP EP02724323A patent/EP1505066B1/en not_active Expired - Lifetime
- 2002-04-19 SK SK5020-2004A patent/SK288052B6/sk not_active IP Right Cessation
- 2002-04-19 ES ES02724323T patent/ES2278018T3/es not_active Expired - Lifetime
- 2002-04-19 JP JP2003586146A patent/JP5142448B2/ja not_active Expired - Lifetime
- 2002-04-19 CN CNB028289870A patent/CN1290843C/zh not_active Ceased
- 2002-04-19 KR KR1020047016676A patent/KR100673140B1/ko not_active Expired - Lifetime
- 2002-04-19 AT AT02724323T patent/ATE347550T1/de active
- 2002-04-19 PT PT02724323T patent/PT1505066E/pt unknown
- 2002-04-19 CZ CZ2004-1122A patent/CZ305162B6/cs not_active IP Right Cessation
- 2002-04-19 SI SI200230485T patent/SI1505066T1/sl unknown
- 2002-04-19 US US10/511,822 patent/US7612095B2/en not_active Expired - Lifetime
- 2002-04-19 NZ NZ536551A patent/NZ536551A/en not_active IP Right Cessation
- 2002-04-19 HR HRP20041048AA patent/HRP20041048B1/hr not_active IP Right Cessation
- 2002-04-19 MX MXPA04010313A patent/MXPA04010313A/es active IP Right Grant
- 2002-04-19 WO PCT/ES2002/000194 patent/WO2003089425A1/es active IP Right Grant
-
2003
- 2003-04-14 PE PE2003000376A patent/PE20040086A1/es active IP Right Grant
- 2003-04-14 UY UY27762A patent/UY27762A1/es not_active Application Discontinuation
- 2003-04-15 AR ARP030101325A patent/AR039423A1/es not_active Application Discontinuation
- 2003-04-16 PA PA20038571201A patent/PA8571201A1/es unknown
-
2004
- 2004-10-17 IL IL164645A patent/IL164645A/en active IP Right Grant
- 2004-11-17 NO NO20044999A patent/NO329327B1/no not_active IP Right Cessation
- 2004-11-18 BG BG108941A patent/BG66302B1/bg unknown
-
2007
- 2007-02-23 CY CY20071100259T patent/CY1107564T1/el unknown
-
2009
- 2009-09-16 US US12/561,148 patent/US20100004285A1/en not_active Abandoned
-
2013
- 2013-04-24 CY CY2013015C patent/CY2013015I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK288052B6 (sk) | Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it | |
| DE60303381T2 (de) | Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel | |
| KR100626109B1 (ko) | 항진균성 결정성 다형체 및 이를 포함하는 약제학적 조성물 | |
| HUT70637A (en) | Tachykinin receptor antagonist benzimidazole derivatives and pharmaceutical compositions containing them | |
| EP0579681B1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| EP0517221B1 (en) | [(Arylalkylpiperidine-4-yl)methyl]-2-alpha,3,4,5-tetrahydro-1(2H)-acenaphthylene-1-ones and related compounds, a process for their preparation and their use as medicaments | |
| DE602004004378T2 (de) | Verbindungen mit einer 5-ht2c rezeptor-wirkung und ihre verwendung | |
| RU2288917C2 (ru) | Полиморф 4-[2-[4-[1-(2-этоксиэтил)-1h-бензимидазол-2-ил]-1-пиперидинил]этил]-альфа, альфа-диметилбензолуксусной кислоты, способ его получения, фармацевтический препарат на его основе и его применение | |
| DE60204046T2 (de) | N-heterocyclylhydrazide als neurotrophe mittel | |
| JP2010013472A (ja) | ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体 | |
| KR100494448B1 (ko) | 항히스타민활성을가지는신규한벤조이미다졸유도체 | |
| HK1072772B (en) | Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic | |
| PL205568B1 (pl) | Polimorf 1 bilastyny, sposoby jego wytwarzania, preparaty farmaceutyczne go zawierające oraz jego zastosowanie | |
| JPH08208640A (ja) | ベンズイミダゾール誘導体およびそれを含有する心不全治療薬 | |
| JPH01113383A (ja) | ２，４−ジアミノ−（ｅ）−６−［２−（３−ピリジル）エテニル］−１，３，５−トリアジンおよび該化合物を有効成分とする抗潰瘍剤 | |
| CZ12566U1 (cs) | Amlodipinhemimaleát a farmaceutický prostředek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of an spc |
Free format text: PRODUCT NAME: BILASTIN; NAT. REGISTRATION NO/DATE: 24/0912/10-S 20110125; FIRST REGISTRATION: IS IS/1/10/002/01 20100923 Spc suppl protection certif: 5007-2013 Filing date: 20130410 |
|
| SPCG | Grant of an spc |
Free format text: PRODUCT NAME: BILASTIN; NAT. REGISTRATION NO/DATE: 24/0912/10-S 20110125; FIRST REGISTRATION: IS IS/1/10/002/01 20100923 Spc suppl protection certif: 166 5007-2013 Filing date: 20130410 Extension date: 20250923 |
|
| MK4A | Patent expired |
Expiry date: 20220419 |